These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 22277301)

  • 1. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm.
    Biederman J; Fried R; Hammerness P; Surman C; Mehler B; Petty CR; Faraone SV; Miller C; Bourgeois M; Meller B; Godfrey KM; Reimer B
    J Psychiatr Res; 2012 Apr; 46(4):484-91. PubMed ID: 22277301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memory loss induced by lisdexamfetamine in the rat: A behavioral, electrophysiological, and histopathological Study.
    Nourirad SN; Bayat AH; Sani M; Beirami A; Hasanzadeh M; Roustaee S; Fathi M; Vakili K; Parvardeh S; Meftahi GH; Sarahian N; Khodagholi F; Aliaghaei A; Abbaszadeh HA; Moghaddam MH
    Behav Brain Res; 2024 May; 465():114963. PubMed ID: 38499158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New onset executive function difficulties at menopause: a possible role for lisdexamfetamine.
    Epperson CN; Shanmugan S; Kim DR; Mathews S; Czarkowski KA; Bradley J; Appleby DH; Iannelli C; Sammel MD; Brown TE
    Psychopharmacology (Berl); 2015 Aug; 232(16):3091-100. PubMed ID: 26063677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing Driving Risk Factors in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD): Insights from EEG and Eye-Tracking Analysis.
    Keren A; Fisher O; Hamde A; Tsafrir S; Ratzon NZ
    Sensors (Basel); 2024 May; 24(11):. PubMed ID: 38894111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of lisdexamfetamine dimesylate on driving behaviors in young adults with ADHD assessed with the Manchester driving behavior questionnaire.
    Biederman J; Fried R; Hammerness P; Surman C; Mehler B; Petty CR; Faraone SV; Miller C; Bourgeois M; Meller B; Godfrey KM; Baer L; Reimer B
    J Adolesc Health; 2012 Dec; 51(6):601-7. PubMed ID: 23174471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
    Babcock T; Dirks B; Adeyi B; Scheckner B
    BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis.
    Fridman M; Hodgkins PS; Kahle JS; Erder MH
    Eur Psychiatry; 2015 Jun; 30(4):521-7. PubMed ID: 25725594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of stimulant and non-stimulant drug treatment on driving performance in patients with attention deficit hyperactivity disorder: a systematic review.
    Gobbo MA; Louzã MR
    Eur Neuropsychopharmacol; 2014 Sep; 24(9):1425-43. PubMed ID: 25044052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.
    Adler LA; Dirks B; Deas P; Raychaudhuri A; Dauphin M; Saylor K; Weisler R
    BMC Psychiatry; 2013 Oct; 13():253. PubMed ID: 24106804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
    Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
    J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD.
    Maneeton N; Maneeton B; Suttajit S; Reungyos J; Srisurapanont M; Martin SD
    Drug Des Devel Ther; 2014; 8():1685-93. PubMed ID: 25336914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Duration of Effect of Open-Label Lisdexamfetamine Dimesylate in Adults With ADHD.
    Adler LA; Lynch LR; Shaw DM; Wallace SP; O'Donnell KE; Ciranni MA; Briggie AM; Faraone SV
    J Atten Disord; 2017 Jan; 21(2):149-157. PubMed ID: 23657761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Mattingly GW; Weisler RH; Young J; Adeyi B; Dirks B; Babcock T; Lasser R; Scheckner B; Goodman DW
    BMC Psychiatry; 2013 Jan; 13():39. PubMed ID: 23356790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study of lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD.
    Kollins SH; English JS; Itchon-Ramos N; Chrisman AK; Dew R; O'Brien B; McClernon FJ
    J Atten Disord; 2014 Feb; 18(2):158-68. PubMed ID: 22508760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Phase 3, Double-Blind, Crossover Comparison of Multilayer, Extended-Release Methylphenidate (PRC-063), and Lisdexamfetamine in the Driving Performance of Young Adults With ADHD.
    Madaan V; Bhaskar S; Donnelly GAE; Cox DJ
    J Atten Disord; 2024 Apr; 28(6):947-956. PubMed ID: 38404033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Impairments Associated With ADHD in Adulthood and the Impact of Pharmacological Treatment.
    Kosheleff AR; Mason O; Jain R; Koch J; Rubin J
    J Atten Disord; 2023 May; 27(7):669-697. PubMed ID: 36876491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of attention-deficit hyperactivity disorder medications in cardiac disease.
    Topriceanu CC; Moon JC; Captur G; Perera B
    Front Neurosci; 2022; 16():1020961. PubMed ID: 36340760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
    Elliott J; Johnston A; Husereau D; Kelly SE; Eagles C; Charach A; Hsieh SC; Bai Z; Hossain A; Skidmore B; Tsakonas E; Chojecki D; Mamdani M; Wells GA
    PLoS One; 2020; 15(10):e0240584. PubMed ID: 33085721
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.